Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Free Cash Flow (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Free Cash Flow for 8 consecutive years, with -$27.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow rose 18.53% year-over-year to -$27.8 million, compared with a TTM value of -$103.1 million through Sep 2025, up 18.13%, and an annual FY2024 reading of -$131.2 million, down 35.89% over the prior year.
  • Free Cash Flow was -$27.8 million for Q3 2025 at X4 Pharmaceuticals, up from -$29.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$12.4 million in Q1 2025 and bottomed at -$68.8 million in Q3 2023.
  • Average Free Cash Flow over 5 years is -$27.4 million, with a median of -$26.5 million recorded in 2023.
  • The sharpest move saw Free Cash Flow crashed 256.24% in 2023, then skyrocketed 63.25% in 2025.
  • Year by year, Free Cash Flow stood at -$19.1 million in 2021, then decreased by 0.32% to -$19.1 million in 2022, then plummeted by 45.25% to -$27.8 million in 2023, then fell by 18.91% to -$33.0 million in 2024, then grew by 15.85% to -$27.8 million in 2025.
  • Business Quant data shows Free Cash Flow for XFOR at -$27.8 million in Q3 2025, -$29.9 million in Q2 2025, and -$12.4 million in Q1 2025.